Simulations Plus (NASDAQ:SLP) posted its earnings results on Sunday. The technology company reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.01, MarketWatch Earnings reports. Simulations Plus had a net margin of 22.96% and a return on equity of 24.44%.
NASDAQ SLP opened at $79.33 on Tuesday. The company has a fifty day moving average price of $65.06 and a 200-day moving average price of $65.43. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of 158.66, a PEG ratio of 7.63 and a beta of -0.17. Simulations Plus has a 1 year low of $26.00 and a 1 year high of $83.78.
SLP has been the topic of a number of recent analyst reports. Raymond James started coverage on shares of Simulations Plus in a research report on Friday, October 16th. They issued an “outperform” rating and a $95.00 price target on the stock. Taglich Brothers upgraded Simulations Plus from a “speculative buy” rating to a “buy” rating and set a $76.00 target price for the company in a report on Wednesday, November 25th. Zacks Investment Research downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Thursday, November 19th. BidaskClub raised Simulations Plus from a “hold” rating to a “buy” rating in a research report on Wednesday, December 23rd. Finally, TheStreet raised shares of Simulations Plus from a “c+” rating to a “b” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Simulations Plus presently has a consensus rating of “Buy” and a consensus target price of $80.40.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.
Featured Story: Analyzing a company’s cash flow statement
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.